NasdaqGS:NVAXBiotechs
Assessing Novavax (NVAX) Valuation After Recent Share Price Swings And Royalty Deal Outlook
Novavax: recent performance snapshot for retail investors
Novavax (NVAX) has drawn attention after recent share price swings, with the stock closing at US$7.97 and showing mixed returns over the past month and past 3 months.
For context, the company reports annual revenue of US$1.12b from recombinant vaccines, including its commercialized COVID-19 product Nuvaxovid and the R21 Matrix-M adjuvant malaria vaccine.
See our latest analysis for Novavax.
The recent 1 day share price return of 3.51%...